Haemophilia Trial, Recruiting NCT07096349 Sponsor: Investigación en Hemofilia y Fisioterapia Condition: Haemophilia
Back to Haemophilia

Haemophilia Trial, Recruiting

NCT07096349
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older.
  • People who have been medically diagnosed with severe haemophilia A, meaning their Factor VIII (a blood clotting protein) level is less than 1%.
  • People who do not currently have inhibitors (substances that block the effects of Factor VIII treatment) at the time of the study.
  • People who have been receiving a type of medication called bispecific monoclonal antibodies for at least 3 months.
  • People who have been medically diagnosed with joint damage caused by haemophilia in at least two joints in the lower limbs, and whose joint health score meets a specific threshold set by the trial (confirm with trial site).
  • People who are able to understand and complete self-administered questionnaires on their own.

Who may not be able to join:

  • People who have been diagnosed with serious muscle, bone, or nerve conditions that cause ongoing chronic pain.
  • People who have neurological or cognitive difficulties that would make it hard to understand or complete the study questionnaires.
  • People who have taken part in another interventional clinical study within the 6 months before this study begins.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rubén Cuesta-Barriuso, PhD, Universidad de Oviedo

Phone: 0034 985103386

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Investigación en Hemofilia y Fisioterapia
Registry
ClinicalTrials.gov
Start date
30 July 2025
Est. completion
3 October 2025

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Assessment of residual chronic pain and its functional interference at the time of the study.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov